Becton, Dickinson and Company (BDX) Scheduled to Post Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) will be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $3.77 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the previous year, the firm posted $2.96 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of BDX stock opened at $236.61 on Thursday. The stock has a market capitalization of $68.38 billion, a price-to-earnings ratio of 52.12, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The company’s fifty day simple moving average is $237.62 and its two-hundred day simple moving average is $235.05. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BDX. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.